These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22669586)

  • 1. Development of bead-based immunoassay to quantify neutralizing antibody for human papillomavirus 16 and 18.
    Liu HB; Chaturvedi PK; Battogtokh G; Bang HJ; Kim IW; Kim YW; Park KS; Ahn WS
    Mol Biotechnol; 2013 Jun; 54(2):361-70. PubMed ID: 22669586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
    Robbins HA; Waterboer T; Porras C; Kemp TJ; Pawlita M; Rodriguez AC; Wacholder S; Gonzalez P; Schiller JT; Lowy DR; Esser M; Matys K; Poncelet S; Herrero R; Hildesheim A; Pinto LA; Safaeian M
    Hum Vaccin Immunother; 2014; 10(10):2965-74. PubMed ID: 25483632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
    Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
    Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.
    Hanumantha Rao N; Baji Babu P; Rajendra L; Sriraman R; Pang YY; Schiller JT; Srinivasan VA
    Vaccine; 2011 Oct; 29(43):7326-34. PubMed ID: 21803095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
    Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M
    Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a 2-plex luminex-based competitive immunoassay to quantify neutralizing antibodies induced by virus-like particles for human papillomavirus 16 and 18.
    Lv P; Zhu H; Wang H; Wang G
    J Biomed Biotechnol; 2011; 2011():272806. PubMed ID: 21808597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies.
    Zhang Y; He Y; Li L; Liang S; Yan M; Ren D; Yang Z; Zhao W; Miao L; Zhang H; Liu Y
    Diagn Pathol; 2018 Aug; 13(1):55. PubMed ID: 30115088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
    Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine.
    Hassan SW; Waheed MT; Müller M; Clarke JL; Shinwari ZK; Lössl AG
    Hum Vaccin Immunother; 2014; 10(10):2975-82. PubMed ID: 25483463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination.
    Scherpenisse M; Schepp RM; Mollers M; Mooij SH; Meijer CJ; Berbers GA; van der Klis FR
    Clin Vaccine Immunol; 2013 Aug; 20(8):1329-32. PubMed ID: 23740920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.
    Bolhassani A; Shirbaghaee Z; Agi E; Davoudi N
    Protein Expr Purif; 2015 Dec; 116():7-11. PubMed ID: 26304732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice.
    Motavalli Khiavi F; Arashkia A; Golkar M; Nasimi M; Roohvand F; Azadmanesh K
    J Immunol Res; 2018; 2018():9464186. PubMed ID: 29854852
    [No Abstract]   [Full Text] [Related]  

  • 18. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.
    Scherpenisse M; Schepp RM; Mollers M; Meijer CJ; Berbers GA; van der Klis FR
    PLoS One; 2013; 8(9):e74797. PubMed ID: 24058629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity.
    Schädlich L; Senger T; Kirschning CJ; Müller M; Gissmann L
    Vaccine; 2009 Mar; 27(10):1511-22. PubMed ID: 19174177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
    Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
    Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.